Ceruletide inhibits phencyclidine-induced dopamine and serotonin release in rat prefrontal cortex

Kazuko Etou, Toshihide Kuroki, Takeshi Kawahara, Yuji Yonezawa, Nobutada Tashiro, Hideyuki Uchimura

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Phencyclidine (PCP; 5.0 mg/kg, IP) produced a greater increase in extracellular dopamine (DA) levels in the prefrontal cortex than in the striatum, while PCP increased the extracellular 5-hydroxytryptamine (serotonin; 5-HT) levels in the prefrontal cortex but not the striatum, as determined by in vivo microdialysis in awake, freely moving rats. The cholecystokinin (CCK)-related decapeptide ceruletide (120 and 400 μg/kg, IP), administered 60 min prior to PCP, significantly attenuated the PCP-induced increase in the extracellular levels of DA and 5-HT in the prefrontal cortex, but not in the striatum. These effects were reversed by PD 135,158, a selective CCK-B receptor antagonist (0.1 mg/kg, SC), administered 5 min prior to ceruletide. When administered alone, ceruletide (400 μg/kg, IP) significantly increased basal extracellular DA levels only in the prefrontal cortex. The selective N-methyl-D-aspartate (NMDA) receptor antagonist dizocilpine (0.5 mg/kg, IP) also increased extracellular DA levels in the prefrontal cortex, but this effect was unaffected by ceruletide pretreatment. These results suggest that ceruletide may differentially modulate basal and PCP-induced release of DA and 5-HT in the prefrontal cortex. Copyright (C) 1998 Elsevier Science Inc.

Original languageEnglish
Pages (from-to)427-434
Number of pages8
JournalPharmacology Biochemistry and Behavior
Volume61
Issue number4
DOIs
Publication statusPublished - Jan 1 1998

Fingerprint

Ceruletide
Phencyclidine
Prefrontal Cortex
Rats
Dopamine
Serotonin
Cholecystokinin B Receptor
Dizocilpine Maleate
Cholecystokinin
N-Methyl-D-Aspartate Receptors
Microdialysis

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Toxicology
  • Pharmacology
  • Clinical Biochemistry
  • Biological Psychiatry
  • Behavioral Neuroscience

Cite this

Ceruletide inhibits phencyclidine-induced dopamine and serotonin release in rat prefrontal cortex. / Etou, Kazuko; Kuroki, Toshihide; Kawahara, Takeshi; Yonezawa, Yuji; Tashiro, Nobutada; Uchimura, Hideyuki.

In: Pharmacology Biochemistry and Behavior, Vol. 61, No. 4, 01.01.1998, p. 427-434.

Research output: Contribution to journalArticle

Etou, Kazuko ; Kuroki, Toshihide ; Kawahara, Takeshi ; Yonezawa, Yuji ; Tashiro, Nobutada ; Uchimura, Hideyuki. / Ceruletide inhibits phencyclidine-induced dopamine and serotonin release in rat prefrontal cortex. In: Pharmacology Biochemistry and Behavior. 1998 ; Vol. 61, No. 4. pp. 427-434.
@article{0e2e5406676342af95ff49f353798fa3,
title = "Ceruletide inhibits phencyclidine-induced dopamine and serotonin release in rat prefrontal cortex",
abstract = "Phencyclidine (PCP; 5.0 mg/kg, IP) produced a greater increase in extracellular dopamine (DA) levels in the prefrontal cortex than in the striatum, while PCP increased the extracellular 5-hydroxytryptamine (serotonin; 5-HT) levels in the prefrontal cortex but not the striatum, as determined by in vivo microdialysis in awake, freely moving rats. The cholecystokinin (CCK)-related decapeptide ceruletide (120 and 400 μg/kg, IP), administered 60 min prior to PCP, significantly attenuated the PCP-induced increase in the extracellular levels of DA and 5-HT in the prefrontal cortex, but not in the striatum. These effects were reversed by PD 135,158, a selective CCK-B receptor antagonist (0.1 mg/kg, SC), administered 5 min prior to ceruletide. When administered alone, ceruletide (400 μg/kg, IP) significantly increased basal extracellular DA levels only in the prefrontal cortex. The selective N-methyl-D-aspartate (NMDA) receptor antagonist dizocilpine (0.5 mg/kg, IP) also increased extracellular DA levels in the prefrontal cortex, but this effect was unaffected by ceruletide pretreatment. These results suggest that ceruletide may differentially modulate basal and PCP-induced release of DA and 5-HT in the prefrontal cortex. Copyright (C) 1998 Elsevier Science Inc.",
author = "Kazuko Etou and Toshihide Kuroki and Takeshi Kawahara and Yuji Yonezawa and Nobutada Tashiro and Hideyuki Uchimura",
year = "1998",
month = "1",
day = "1",
doi = "10.1016/S0091-3057(98)00128-2",
language = "English",
volume = "61",
pages = "427--434",
journal = "Pharmacology Biochemistry and Behavior",
issn = "0091-3057",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Ceruletide inhibits phencyclidine-induced dopamine and serotonin release in rat prefrontal cortex

AU - Etou, Kazuko

AU - Kuroki, Toshihide

AU - Kawahara, Takeshi

AU - Yonezawa, Yuji

AU - Tashiro, Nobutada

AU - Uchimura, Hideyuki

PY - 1998/1/1

Y1 - 1998/1/1

N2 - Phencyclidine (PCP; 5.0 mg/kg, IP) produced a greater increase in extracellular dopamine (DA) levels in the prefrontal cortex than in the striatum, while PCP increased the extracellular 5-hydroxytryptamine (serotonin; 5-HT) levels in the prefrontal cortex but not the striatum, as determined by in vivo microdialysis in awake, freely moving rats. The cholecystokinin (CCK)-related decapeptide ceruletide (120 and 400 μg/kg, IP), administered 60 min prior to PCP, significantly attenuated the PCP-induced increase in the extracellular levels of DA and 5-HT in the prefrontal cortex, but not in the striatum. These effects were reversed by PD 135,158, a selective CCK-B receptor antagonist (0.1 mg/kg, SC), administered 5 min prior to ceruletide. When administered alone, ceruletide (400 μg/kg, IP) significantly increased basal extracellular DA levels only in the prefrontal cortex. The selective N-methyl-D-aspartate (NMDA) receptor antagonist dizocilpine (0.5 mg/kg, IP) also increased extracellular DA levels in the prefrontal cortex, but this effect was unaffected by ceruletide pretreatment. These results suggest that ceruletide may differentially modulate basal and PCP-induced release of DA and 5-HT in the prefrontal cortex. Copyright (C) 1998 Elsevier Science Inc.

AB - Phencyclidine (PCP; 5.0 mg/kg, IP) produced a greater increase in extracellular dopamine (DA) levels in the prefrontal cortex than in the striatum, while PCP increased the extracellular 5-hydroxytryptamine (serotonin; 5-HT) levels in the prefrontal cortex but not the striatum, as determined by in vivo microdialysis in awake, freely moving rats. The cholecystokinin (CCK)-related decapeptide ceruletide (120 and 400 μg/kg, IP), administered 60 min prior to PCP, significantly attenuated the PCP-induced increase in the extracellular levels of DA and 5-HT in the prefrontal cortex, but not in the striatum. These effects were reversed by PD 135,158, a selective CCK-B receptor antagonist (0.1 mg/kg, SC), administered 5 min prior to ceruletide. When administered alone, ceruletide (400 μg/kg, IP) significantly increased basal extracellular DA levels only in the prefrontal cortex. The selective N-methyl-D-aspartate (NMDA) receptor antagonist dizocilpine (0.5 mg/kg, IP) also increased extracellular DA levels in the prefrontal cortex, but this effect was unaffected by ceruletide pretreatment. These results suggest that ceruletide may differentially modulate basal and PCP-induced release of DA and 5-HT in the prefrontal cortex. Copyright (C) 1998 Elsevier Science Inc.

UR - http://www.scopus.com/inward/record.url?scp=0031795931&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031795931&partnerID=8YFLogxK

U2 - 10.1016/S0091-3057(98)00128-2

DO - 10.1016/S0091-3057(98)00128-2

M3 - Article

VL - 61

SP - 427

EP - 434

JO - Pharmacology Biochemistry and Behavior

JF - Pharmacology Biochemistry and Behavior

SN - 0091-3057

IS - 4

ER -